Background Treatment options for women presenting with triple negative breast cancer
(TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with …

Triple-negative (TNBC) is the most lethal subtype of breast cancer owing to high
heterogeneity, aggressive nature, and lack of treatment options. Chemotherapy remains the …

Triple-negative breast cancer (TNBC) is the most complex, aggressive and fatal subtype of
breast cancer. Owing to the lack of targeted therapy and heterogenic nature of TNBC …

Simple Summary Triple-negative breast cancer (TNBC) is a highly aggressive subtype of
breast cancer that cannot be treated with endocrine therapy and Her2-targeted therapy …

Simple Summary Triple Negative Breast Cancer represents a cancer type with an unmet
clinical need. This type of breast cancer presents the worse clinical outcome due to its …

Triple negative breast cancer (TNBC) is classically treated with combination
chemotherapies. Although, initially responsive to chemotherapies, TNBC patients frequently …

Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy
compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is …

Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …

Triple negative breast cancer (TNBC) a clinically aggressive subtype of breast cancer with
poor outcomes. Chromosomal instability is a hallmark of many TNBCs, and likely underlies …

Triple‐negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular
subtypes that respond differentially to chemotherapy and targeted agents. The absence of …